Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMIR MORADI

Allopathic & Osteopathic Physicians Otolaryngology

NPI
1467567032
CMS profile
21600
Location
VISTA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$106,462.06

142 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $104,457.89 132
Merz North America, Inc. $1,185.30 5
Allergan, Inc. $767.00 2
Galderma Laboratories, L.P. $51.87 3

Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMIR MORADI

NPI 1467567032 · CMS profile ID 21600

Allopathic & Osteopathic Physicians / Otolaryngology

VISTA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467567032?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMIR MORADI, NPI 1467567032, CMS profile ID 21600. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467567032?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AMIR MORADI, NPI 1467567032, CMS profile ID 21600. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467567032?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AMIR MORADI, NPI 1467567032, CMS profile ID 21600, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1467567032?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

142 matching records · $106,462.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 142 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–142 of 142.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $197.1605/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946753 CMS
ABBVIE INC. $28.4205/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946749 CMS
ABBVIE INC. $10.1704/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946737 CMS
ABBVIE INC. $8.4504/18/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946739 CMS
ABBVIE INC. $8.4504/18/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946741 CMS
ABBVIE INC. $8.4504/18/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946743 CMS
ABBVIE INC. $8.4504/18/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946745 CMS
ABBVIE INC. $8.4504/18/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946747 CMS
ABBVIE INC. $8.4504/17/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946727 CMS
ABBVIE INC. $8.4504/17/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946729 CMS
ABBVIE INC. $8.4504/17/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946731 CMS
ABBVIE INC. $8.4504/17/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946733 CMS
ABBVIE INC. $8.4504/17/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946735 CMS
ABBVIE INC. $4.1504/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946715 CMS
ABBVIE INC. $51.6604/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946717 CMS
ABBVIE INC. $28.7704/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946719 CMS
ABBVIE INC. $1,344.8004/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946721 CMS
ABBVIE INC. $193.9304/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946723 CMS
ABBVIE INC. $23.8404/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946725 CMS
ABBVIE INC. $197.6704/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946711 CMS
ABBVIE INC. $203.6304/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946713 CMS
ABBVIE INC. $88.5004/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946709 CMS
ABBVIE INC. $2,250.0004/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946707 CMS
ABBVIE INC. $161.7003/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946705 CMS
Galderma Laboratories, L.P. $15.3402/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059715661 CMS
ABBVIE INC. $67.1002/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946699 CMS
ABBVIE INC. $9,000.0002/14/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946701 CMS
ABBVIE INC. $32.9702/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946703 CMS
ABBVIE INC. $8.4502/06/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946687 CMS
ABBVIE INC. $8.4502/06/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946689 CMS
ABBVIE INC. $8.4502/06/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946691 CMS
ABBVIE INC. $8.4502/06/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946693 CMS
ABBVIE INC. $8.4502/06/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946695 CMS
ABBVIE INC. $8.4502/06/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946697 CMS
ABBVIE INC. $98.2402/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946681 CMS
ABBVIE INC. $8.4502/02/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946683 CMS
ABBVIE INC. $8.4502/02/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946685 CMS
ABBVIE INC. $12.1201/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946679 CMS
Allergan, Inc. $167.7001/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 973114573 CMS
ABBVIE INC. $1,800.0001/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997946677 CMS
Merz North America, Inc. $165.3601/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051003169 CMS
Allergan, Inc. $599.3001/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 973114569 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,053.67 55
PY2020 $21,079.32 52
PY2021 $25,313.95 41
PY2022 $54,408.16 84
PY2023 $106,462.06 142
PY2024 $40,384.79 57
PY2025 $99,578.10 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,096.14 10
PY2025 Principal investigator $412,870.19 52
PY2024 Recipient $5,554.09 7
PY2024 Principal investigator $397,468.47 41
PY2023 Recipient $76,870.40 22
PY2023 Principal investigator $251,871.43 18
PY2022 Recipient $383.27 6
PY2022 Principal investigator $825,888.74 38
PY2021 Recipient $4,181.39 8
PY2021 Principal investigator $149,420.00 14
PY2020 Principal investigator $75,244.40 16
PY2019 Principal investigator $79,951.00 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $8,681.64 12/31/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Prospective, Open-Label Study to Evaluate Subject Satisfaction with Overall Facial Appearance After Treatment with JUVeDERM Products in Medical Weight Loss (MWL) Subjects No dispute reported 06/30/2026 1202534891
Principal investigator 1 ABBVIE INC. $916.68 12/31/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study No dispute reported 06/30/2026 1202534893
Principal investigator 1 ABBVIE INC. $31,356.26 12/31/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid-Face Soft Tissue Augmentation No dispute reported 06/30/2026 1202534895
Principal investigator 1 ABBVIE INC. $2,400.00 12/30/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate the Safety and Effectiveness of JUVEDERM Products in Adult Participants for the Change of Their Overall Facial Appearance No dispute reported 06/30/2026 1202532254
Principal investigator 1 ABBVIE INC. $1,784.00 12/18/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202531376
Principal investigator 1 ABBVIE INC. $366.25 12/04/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202529106
Principal investigator 1 ABBVIE INC. $225.00 12/04/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202529108
Principal investigator 1 ABBVIE INC. $51,115.50 12/04/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202529110
Principal investigator 1 ABBVIE INC. $4,262.50 11/12/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202523843
Principal investigator 1 ABBVIE INC. $3,341.25 11/12/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202523853
Principal investigator 1 ABBVIE INC. $3,988.75 11/12/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202523855
Principal investigator 1 ABBVIE INC. $4,360.00 11/12/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202523859
Principal investigator 1 ABBVIE INC. $5,403.75 11/11/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202523745
Principal investigator 1 ABBVIE INC. $1,012.00 11/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202523265
Principal investigator 1 ABBVIE INC. $2,000.00 11/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202523281
Principal investigator 1 ABBVIE INC. $5,124.00 11/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202523283
Principal investigator 1 ABBVIE INC. $2,500.00 11/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate the Safety and Effectiveness of JUVEDERM Products in Adult Participants for the Change of Their Overall Facial Appearance No dispute reported 06/30/2026 1202523325
Principal investigator 1 ABBVIE INC. $2,050.00 11/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder No dispute reported 06/30/2026 1202523327
Principal investigator 1 ABBVIE INC. $450.00 11/05/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202521879
Principal investigator 1 ABBVIE INC. $9,000.00 11/05/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate the Safety and Effectiveness of JUVEDERM Products in Adult Participants for the Change of Their Overall Facial Appearance No dispute reported 06/30/2026 1202522037
Principal investigator 1 ABBVIE INC. $3,500.00 11/05/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars No dispute reported 06/30/2026 1202522039
Principal investigator 1 ABBVIE INC. $1,253.40 11/05/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202522041
Principal investigator 1 ABBVIE INC. $2,498.72 11/05/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202522085
Principal investigator 1 ABBVIE INC. $1,450.00 10/09/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202514697
Principal investigator 1 ABBVIE INC. $96,032.08 10/09/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202514699
Principal investigator 1 ABBVIE INC. $2,438.60 10/09/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202514701
Recipient ABBVIE INC. $656.47 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202400028
Recipient ABBVIE INC. $21.48 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202400032
Recipient ABBVIE INC. $53.69 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202400036
Recipient ABBVIE INC. $32.35 10/04/2025 Covered Recipient Physician A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scars No dispute reported 06/30/2026 1202400041
Recipient ABBVIE INC. $49.06 10/04/2025 Covered Recipient Physician A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scars No dispute reported 06/30/2026 1202400044
Recipient ABBVIE INC. $125.35 10/03/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202400017
Recipient ABBVIE INC. $68.69 10/03/2025 Covered Recipient Physician A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scars No dispute reported 06/30/2026 1202400021
Recipient ABBVIE INC. $46.48 10/03/2025 Covered Recipient Physician A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scars No dispute reported 06/30/2026 1202400025
Principal investigator 1 ABBVIE INC. $3,988.75 09/04/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202508546
Principal investigator 1 ABBVIE INC. $4,277.50 09/04/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202508548
Principal investigator 1 ABBVIE INC. $5,995.00 09/04/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202508550
Principal investigator 1 ABBVIE INC. $4,945.40 09/04/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202509974
Principal investigator 1 ABBVIE INC. $8,879.00 09/04/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202509976
Principal investigator 1 ABBVIE INC. $3,405.00 08/21/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202505517
Principal investigator 1 ABBVIE INC. $9,030.00 08/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202503473
Principal investigator 1 ABBVIE INC. $2,472.70 08/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202503475
Principal investigator 1 ABBVIE INC. $9,458.75 07/08/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202497056
Principal investigator 1 ABBVIE INC. $8,603.30 07/02/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202494297
Recipient ABBVIE INC. $16.40 06/12/2025 Covered Recipient Physician A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202400010
Recipient ABBVIE INC. $26.17 06/12/2025 Covered Recipient Physician A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202400013
Principal investigator 1 ABBVIE INC. $7,315.80 06/03/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202488037
Principal investigator 1 ABBVIE INC. $11,429.38 06/03/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202488041
Principal investigator 1 ABBVIE INC. $6,171.30 05/07/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202483711
Principal investigator 1 ABBVIE INC. $12,491.25 05/07/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202483859
Principal investigator 1 ABBVIE INC. $11,272.90 04/03/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202472425
Principal investigator 1 ABBVIE INC. $13,044.38 04/03/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202472428
Principal investigator 1 ABBVIE INC. $3,472.00 04/01/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Upper Facial Lines (Glabellar Lines Lateral Canthal Lines and Forehead Lines) No dispute reported 06/30/2026 1202467902
Principal investigator 1 ABBVIE INC. $13,787.50 03/07/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
M24-704 - A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202460516
Principal investigator 1 ABBVIE INC. $6,246.10 03/07/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202460520
Principal investigator 1 Galderma Laboratories, L.P. $1,000.00 03/07/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A Prospective Open-label Study to Evaluate Safety and Effectiveness of Two Different Reconstitution Volumes of Poly-l-lactic Acid (PLLA) for Correction of Wrinkles in the dcolletage Area No dispute reported 06/30/2026 1234513577
Principal investigator 1 ABBVIE INC. $1,500.00 02/21/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satisfaction and benefits of long-term repeated BOTOX treatment for upper facial lines No dispute reported 06/30/2026 1202453568
Principal investigator 1 ABBVIE INC. $1,500.00 02/21/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satisfaction and benefits of long-term repeated BOTOX treatment for upper facial lines No dispute reported 06/30/2026 1202453572
Principal investigator 1 ABBVIE INC. $1,500.00 02/21/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satisfaction and benefits of long-term repeated BOTOX treatment for upper facial lines No dispute reported 06/30/2026 1202453575
Principal investigator 1 ABBVIE INC. $1,710.00 02/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
M22-974 - A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Upper Facial Lines (Glabellar Lines Lateral Canthal Lines and Forehead Lines) No dispute reported 06/30/2026 1202448345
Principal investigator 1 ABBVIE INC. $10,271.40 02/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202448350
Principal investigator 1 ABBVIE INC. $1,592.40 01/02/2025 Non-covered Recipient Entity
PACIFIC CLINICAL INNOVATIONS INC
M22-974 - A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Upper Facial Lines (Glabellar Lines Lateral Canthal Lines and Forehead Lines) No dispute reported 06/30/2026 1202434823